// May 14, 2026 | American Society of Gene and Cell Therapy (ASGCT)
Harnessing a diverse collection of CRISPR-associated RNA-guided nucleases and novel reverse transcriptases for precise gene editing
Drew Kelso
Associate Director, Translational Biology, ElevateBio
This presentation highlights reverse transcriptase (RT) editing, a next-generation gene editing approach that enables precise and versatile rewriting of specific DNA sequences. We mined ElevateBio’s massive bioinformatic database, comprised of over 10 billion natural proteins, and identified a diverse collection of CRISPR-associated RNA-guided nucleases (LEGs) and novel RT enzymes. These RT editing systems were optimized and engineered to achieve high levels of editing both in vitro and in vivo.